Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebapivat in Participants With Sickle Cell Disease
NCT06924970Phase 2Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of tebapivat in sickle cell disease (SCD), sponsored by Agios Pharmaceuticals. Started May 2025; status: active, not recruiting.
02
Drugs
tebapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06924970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924970.